April 12, 2022 5:39pm

Inflation data out of Washington showed prices in March further accelerated to a new 40-year high; if investors need to raise cash, not from this sector they won’t

Pre-open indications: 4 HITs and 4 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.


The Dow closed DOWN -87.72 points (-0.26%); the S&P closed DOWN -15.84 points (-0.34%) while the Nasdaq closed DOWN -40.38 points (-0.30%)



Indexes fell on Tuesday, after an early morning bounce gave way to selling as investors weighed the latest U.S. inflation data. The report showed another sharp increase in prices for last month.

Consumer prices in March surged 8.5% from a year ago, slightly higher than expected and at their highest levels since 1981, according to data from the Labor Department on Tuesday. Meanwhile, core CPI — which excludes food and energy prices — rose less than expected; it climbed 0.3% in March, while economists polled by Dow Jones expected a gain of 0.5%. Core prices on an annual basis were up 6.5%. <CNBC>


Pre-open post: RegMed Investors’ (RMi) pre-open: CPI +8.5% inflation release clouds the markets. Another indication, the aftermarket was weak although a few sector equities are flashing upside benefit.” … https://www.regmedinvestors.com/articles/12384


RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Tuesday opened positive at 28 up/4 downs, 3 flats, slipped negaive at the mid-day at 13/21 and 1 flat, ending with a negative close of 10/24 and 1 flat;
  • Monday opened negative at 0 up/35 downs, stayed negative at the mid-day at 2/32 and 1 flat, ending with a negative close of 1/33 and 1 flat,


52-week or all-time lows:

  • Adverum Biotechnologies (ADVM) at $1.15
  • Homology Medicine (FIXX) at $2.30


Pre-open Indications: 4 HITs: <Biostage (BSTG) closed up $0.30 with 1,634 shares traded after Monday’s flat with 25 shares traded, Caribou Biosciences (CRBU +$0.14), Chinook Therapeutics (KDNY -$0.01), Ionis Pharmaceuticals (IONS +$0.02)> 4 MIS <BioLife Solutions (BLFS -$0.97), Sage Therapeutics (SAGE -$0.23), Verastem (VSTM -$0.05), Alnylam Pharmaceuticals (ALNY +$2.15),   


Key Metrics:

  • Tuesday - Sector volume was LOW with 1 of the 10-upside having higher than the 3-month average volume with LOW volume of 1 of 24-downside having higher than the 3-month average volume;
  • Monday - Sector volume was LOW with 1 of the 1-upside having higher than the 3-month average volume with LOW volume of 5 of 33-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was down -0.77% and the XBI was down -0.19%
  • Monday, the IBB was down -2.30% and the XBI was down -3.40%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.11 points or -0.45% at 24.26
  • Monday was up +3.21 points or +15.17 % at 24.37


Jumping with share pricing momentum (10 of 10):

  • CRISPR Therapeutics (CRSP +$2.13),
  • Alnylam Pharmaceuticals (ALNY +$2.12 after Monday’s -$5.99),
  • Ultragenyx (RARE +$1.34 after Monday’s -$2.62),
  • Global Blood Therapeutics (GBT +$0.68),
  • Fate Therapeutics (FATE +$0.61 after Monday’s -$2.15),
  • Beam Therapeutics (BEAM +$0.43 after Monday’s -$2.76),
  • AxoGen (AXGN +$0.12),
  • MiMedx (MDXG +$0.105),
  • Editas Medicine (EDIT +$0.08 after Monday’s -$0.78),
  • Avrobio (AVRO +$0.0005),

Hammered in today’s market (10 of 24):

  • BioLife Solutions (BLFS -$0.92 after Monday’s -$0.38),
  • Sage Therapeutics (SAGE -$0.67),
  • Intellia Therapeutics (NTLA -$0.62 after Monday’s -$1.33),
  • Vericel (VCEL -$0.61 after Monday’s -$0.51),
  • Regenxbio (RGNX -$0.54),
  • Biostage (BSTG -$0.30 after Tuesday’s $0.00),
  • Voyager Therapeutics (VYGR -$0.14),
  • Cellectis SA (CLLS -$0.135),
  • Precigen (PGEN -$0.132),
  • uniQure NV (QURE -$0.13 after Monday’s +$0.08),


  • Agenus (AGEN)


April, Q2/2022:

  • Tuesday closed negative with 10 incliners, 24 decliners and 1 flat
  • Monday closed negative with 1 incliner, 33 decliners and 1 flat


The BOTTOM LINE: No Rice Krispie’s today as the market’s milk sours.

The sector rally opened solidly higher as the consumer price index raised hopes that inflation is peaking, but the major indexes reversed lower as a top Fed official signaled aggressive rate hikes and other measures are ahead. <IBD>

After the worst session in more than a while, the oversold were again mostly undervalued.

I STILL believe, lows are looking appetizing after going as even to LOWER levels on Monday and Tuesday.

As I stated in last Friday night’s post, “What justifies the share pricing, it’s NOT investor advocacy?  The short-term and near-term pricing “shades” the long-term price targets.”

Volume again was also barely there … as many companies prepare for a Q1/22 response to earnings – and it might get even more ugly.

I am more than worried about investment bank pricey analyst valuations that (in my mind’s eye) have NO basis.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.